Hervé Tiriac

Salk Institute for Biological Studies — United States

Medicine · Health Sciences

27h-index10.9kcitations217works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(120), Cancer Cells and Metastasis(64), Cancer Genomics and Diagnostics(41), Cancer Research and Treatments(41), Pancreatic function and diabetes(27)

Publications217 total

Abstract B027: Synergism of SUMOylation Inhibition with Irinotecan for the Treatment of Pancreatic Cancer
Cancer Research·2025
Abstract B040: WNK kinases in pancreatic cancer: Novel regulators of macropinocytosis and potentiators of glutamine-targeted therapy
Cancer Research·2025
Abstract A109: Actin cytoskeleton dynamics in tumor cells mediate Immune-suppressive microenvironment and sensitize pancreas tumors to PD-1 blockade therapy
Cancer Research·2025
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer
2025Open Access
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Journal of Clinical Investigation·2025· 4 citedOpen Access
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC
Nature Chemical Biology·2025· 1 citedOpen Access
Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer
2025Open Access
Abstract LB282: Overcoming chemotherapy resistance in pancreatic cancer: The impact of novel RAS inhibitors and tumor microenvironment modulation
Cancer Research·2025
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Nature·2025· 40 cited
Abstract 2582: Silencing MICAL2 expression in pancreatic cancer cells rewires the tumor microenvironment through the IL1-a/p38 MAP kinase/STAT-3 axis and sensitizes tumors to immune checkpoint blockade therapy
Cancer Research·2025
Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma
Journal of Pharmacology and Experimental Therapeutics·2025· 2 citedOpen Access
Supplementary Tables S1-S6 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
Data from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
Supplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
Supplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
2025Open Access
MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Cancer Research·2025· 5 citedOpen Access
SUMO Inhibition Plus CD40 Agonism Increases Anti-Tumor Immunogenicity Through Interferon Mediated Macrophage Activation
2024· 1 citedOpen Access
Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics
2024Open Access
page 1 of 11Next →

Frequent Co-authors

David A. Tuveson(27), Dannielle D. Engle(14), Andrew M. Lowy(14), Lindsey A. Baker(8), Youngkyu Park(8), Chang‐Il Hwang(6), Dennis Plenker(6), Jonathan M. Buscaglia(6), Michael A. Hollingsworth(6), Jonathan Weitz(6), Tobiloba E. Oni(5), Kenneth H. Yu(5), Ralph H. Hruban(5), Tim D.D. Somerville(5), Christopher R. Vakoc(5), Edgar Esparza(5), Daniel Öhlund(4), Mariano Ponz‐Sarvisé(4), Iok In Christine Chio(4), Hans Clevers(4)